Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04160312
Other study ID # AFCRO-110 / 19.01.AMZ
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 8, 2019
Est. completion date March 31, 2020

Study information

Verified date April 2020
Source Amazentis SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, two-period, crossover, randomized, open labelled study enrolling 100 healthy subjects to evaluate the Urolithin A producer status and to compare bioavailabilty of direct dietary supplementation with Mitopure™ (proprietary Urolithin A) to dietary exposure with pomegranate juice


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date March 31, 2020
Est. primary completion date February 29, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Males and females 18 to 80 years of age;

2. Is in general good health, as determined by the clinical research team;

3. Willingness to consume investigational product, complete questionnaires and to complete all clinic visits;

4. Have given voluntary, written, informed consent to participant in the study;

Exclusion Criteria:

1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial;

2. Alcohol or drug abuse within the last 6 months;

3. Volunteers who plan to donate blood during the study or within 30 days of completing the study;

4. Subject has a known allergy to the test material's active or inactive ingredients;

5. Subjects with unstable medical conditions;

6. Clinically significant abnormal laboratory results at screening;

7. Participation in a clinical research trial within 30 days prior to randomization;

8. Allergy or sensitivity to study ingredients; lactose intolerance.

9. Individuals who are cognitively impaired and/or who are unable to give informed consent;

10. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.

11. Has taken antibiotics within the previous 30 days;

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Mitopure™ (Proprietary Urolithin A)
Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
Pomegranate Juice
100% Pomegranate juice (approximately 1 glass equivalent)

Locations

Country Name City State
United States Atlantia Food Clinical Trials CRO (Northwestern University campus) Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Amazentis SA Atlantia Food Clinical Trials

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute change from T0 to T+24 hours in the Urolithin A (UA) group as compared to Pomegranate Juice (PJ) group in UA- glucuronide plasma levels. 2 days
Secondary Absolute change from T0 to T+24 hours in the UA group as compared to PJ group in UA- glucuronide blood spot levels 2 days
Secondary Absolute change from T0 to T+6 hours in the UA group as compared to PJ group in UA- glucuronide plasma levels. 1 day
Secondary Absolute change from T0 to T+6 hours in the UA group as compared to PJ group in UA- glucuronide blood spot levels. 1 day
Secondary Change in AUC from T0 to T+6 and/or T+24 in the UA group as compared to the PJ group in UA glucuronide levels 2 days
Secondary Absolute change from T0 to T6 hours and/or to T24 hours in the UA group as compared to PJ group in UA aglycone (parent) plasma levels 2 days
Secondary Change in AUC from T0 to T+6 and/or T+24 in the UA group as compared to the PJ group in UA aglycone (parent) plasma levels 2 days
Secondary Absolute change from T0 to T6 hours and/or to T24 hours in the UA group as compared to PJ group in UA sulfate plasma levels 2 days
Secondary Change in AUC from T0 to T6 hours and/or to T24 hours in the UA group as compared to PJ group in UA sulfate plasma levels 2 days
Secondary To assess prevalence of UA producers following consumption of fixed volume of Pomegranate juice in a healthy US population 2 days
Secondary Differences between UA producers and non-producers at baseline for Hand grip strength using a calibrated JAMAR® Hydraulic Hand Dynamometer 2 days
Secondary Differences between UA producers and non-producers at baseline for gait speed using the 4-meter gait speed test 2 days
Secondary Differences between UA producers and non-producers at baseline for physical activity levels assessed via the International Physical Activity Questionnaire. Questionnaire consists of questions that provide information on the physical activity in the last 7 days. Activities include total of duration and frequency from walking, moderate activity and severe physical activity. Accordingly,there are 3 activity levels: Inactive,minimal active and very active.The lowest level of physical activity is inactive and the highest level of physical activity is very active. 2 days
Secondary Differences between UA producers and non-producers at baseline for energy levels assessed via the Lee-Visual Analogue Scale to assess Fatigue (VAS-F). The scale consists of 18 items relating to the subjective experience of fatigue. Scores fall between 0 (not fatigued at all) and 100 (extremely fatigued). 2 days
Secondary Differences between UA producers and non-producers at baseline for gut microbiome. Fecal samples will be used to extract DNA and shotgun sequencing will be performed to assess global microbiome differences at the species level. 2 days
Secondary Differences between UA producers and non-producers at baseline for plasma metabolome. Metabolites in serum will be measured by metabolomic mass spectrometry 2 days
Secondary Differences between UA producers and non-producers at baseline for blood biochemistry metabolic profile as assessed via lipid profile in plasma. 2 days
Secondary Differences in consumer perception on the study investigation food products overall taste using a consumer perception Likert scale Scale, of 1 to 5 where 1 is dislike extremely and 5 is like extremely 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1